metaraminol 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 1721 | 54-49-9 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A sympathomimetic agent that acts predominantly at alpha-1 adrenergic receptors. It has been used primarily as a vasoconstrictor in the treatment of HYPOTENSION.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 50 | mg | P |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 49.82 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Sept. 29, 1954 | FDA |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Mental status changes postoperative | 74.03 | 63.78 | 9 | 277 | 191 | 63488545 |
| Confusion postoperative | 72.17 | 63.78 | 9 | 277 | 237 | 63488499 |
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | C01CA09 | CARDIOVASCULAR SYSTEM CARDIAC THERAPY CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES Adrenergic and dopaminergic agents |
| MeSH PA | D018663 | Adrenergic Agents |
| MeSH PA | D000322 | Adrenergic Agonists |
| MeSH PA | D058646 | Adrenergic alpha-1 Receptor Agonists |
| MeSH PA | D000316 | Adrenergic alpha-Agonists |
| MeSH PA | D002317 | Cardiovascular Agents |
| MeSH PA | D018377 | Neurotransmitter Agents |
| MeSH PA | D018373 | Peripheral Nervous System Agents |
| MeSH PA | D013566 | Sympathomimetics |
| MeSH PA | D014662 | Vasoconstrictor Agents |
| CHEBI has role | CHEBI:35524 | sympathomimetic |
| CHEBI has role | CHEBI:35569 | alpha-adrenergic agonists |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Low blood pressure | indication | 45007003 | |
| Priapism | off-label use | 6273006 | DOID:9286 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 9.51 | acidic |
| pKa2 | 12.54 | acidic |
| pKa3 | 8.86 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Alpha-1A adrenergic receptor | GPCR | AGONIST | WOMBAT-PK | CHEMBL | |||||
| Macrophage migration inhibitory factor | Unclassified | Ki | 4.11 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4017958 | VUID |
| N0000178937 | NUI |
| D01019 | KEGG_DRUG |
| 33402-03-8 | SECONDARY_CAS_RN |
| 4017958 | VANDF |
| 4019818 | VANDF |
| C0025575 | UMLSCUI |
| CHEBI:6794 | CHEBI |
| CHEMBL1201319 | ChEMBL_ID |
| DB00610 | DRUGBANK_ID |
| CHEMBL2062262 | ChEMBL_ID |
| D008680 | MESH_DESCRIPTOR_UI |
| 5906 | PUBCHEM_CID |
| 34 | INN_ID |
| 7229 | IUPHAR_LIGAND_ID |
| 818U2PZ2EH | UNII |
| 6805 | RXNORM |
| 5061 | MMSL |
| d00702 | MMSL |
| 001824 | NDDF |
| 004735 | NDDF |
| 372728001 | SNOMEDCT_US |
| 41015006 | SNOMEDCT_US |
| 58461000 | SNOMEDCT_US |
Pharmaceutical products:
None